Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

Maverick Medical AI Closes a $5 Million Seed Investment Round for Accelerating Development of its mCoder Artificial Intelligence Platform for Additional Clinical Domains

Maverick Medical AI has announced that it has closed a $5 million seed investment from leading investors in the healthcare IT industry. The round was led by venture capital funds Lionbird and Firstime Ventures, together with entrepreneur investors Ariel MaislosOfir ShalviEhud Weinstein and Eli Ben Dor. The Company previously raised a total of $2 million in pre-seed investment.

Maverick offers a cutting-edge AI platform, mCoder, that addresses the medical coding efficiency, accuracy, and capacity challenges impacting the healthcare revenue cycle by providing a single SaaS platform for healthcare providers across all care settings.

Recommended AI News: Red Hat Helps Türk Telekom Digitally Transform Across its Business to the Edge

The mCoder platform is based on the most advanced deep learning AI technology backed up with proprietary algorithms that generate synthetic data, enabling the platform to support superior coding of patient reports in multiple clinical specialties. Maverick’s platform is the first to address multiple clinical specialties and to enable standardized coding.

Related Posts
1 of 30,271

Maverick’s platform has been validated and used by several leading U.S. healthcare providers in the $16.4 billion U.S. medical coding market (2020 figures).

Yossi Shahak, Maverick’s CEO noted, “The addition of these top-tier investors to our company is a vote of confidence for our highly differentiated AI platform. We are excited to scale our R&D and sales teams to provide our solution for a wider range of clinical domains. Our unique offering is generating significant interest from U.S. providers, and we look forward to expanding our partnerships and customer base.”

Recommended AI News: LiveRamp Embedded Identity is Now Available in the Snowflake Media Data Cloud

[To share your insights with us, please write to]

Comments are closed.